Exclusive

Publication

Byline

Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... Read More


Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... Read More


Singapore Clinical Trial: A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugat... Read More


Singapore Clinical Trial: A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY® Kids)

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the p... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection ... Read More


Singapore Clinical Trial: Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)'. The following are the oth... Read More


Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More


Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More


Singapore Clinical Trial: A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and... Read More


Singapore Clinical Trial: ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In... Read More